Proteomics in biomarker discovery and drug development

Journal of Cellular Biochemistry

Volumn 89, Issue 5, 2003, Pages 868-886

  He, Qing Yu ^a,b   Chiu, Jen Fu ^a,b  

^a UNIVERSITY OF HONG KONG   (Hong Kong)

^b UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

Biomarker; Drug discovery; Proteomic application; Proteomics

Indexed keywords

BIOLOGICAL MARKER;

ARTICLE; BIOINFORMATICS; DRUG DEVELOPMENT; GENOMICS; MEDICAL RESEARCH; MOLECULAR DYNAMICS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEOMICS;

ANIMALS; BIOLOGICAL MARKERS; COMPUTATIONAL BIOLOGY; DRUG DESIGN; GENOMICS; HUMANS; PROTEOMICS; TECHNOLOGY, PHARMACEUTICAL;

EID: 0042268086     PISSN: 07302312     EISSN: None     Source Type: Journal    
DOI: 10.1002/jcb.10576     Document Type: Article

References (212)

1. Adam GC, Cravatt BF, Sorensen EJ. 2001. Profiling the specific reactivity of the proteome with non-directed activity-based probes. Chem Biol 8:81-95.
2. Adam BL, Qu Y, Davis JW, Ward MD, Clements MA, Cazares LH, Semmes OJ, Schellhammer PF, Yasui Y, Feng Z, Wright GL, Jr. 2002a. Serum protein fingerprinting coupled with a pattern-matching algorithm distinguishes prostate cancer from benign prostate hyperplasia and healthy men. Cancer Res 62:3609-3614.
3. Adam GC, Sorensen EJ, Cravatt BF. 2002b. Chemical strategies for functional proteomics. Mol Cell Proteomics 1:781-790.
4. Adam GC, Sorensen EJ, Cravatt BF. 2002c. Proteomic profiling of mechanistically distinct enzyme classes using a common chemotype. Nat Biotechnol 20:805-809.
5. Adam GC, Sorensen EJ, Cravatt BF. 2002d. Trifunctional chemical probes for the consolidated detection and identification of enzyme activities from complex proteomes. Mol Cell Proteomics 1:828-835.
6. Adam PJ, Boyd R, Tyson KL, Fletcher GC, Stamps A, Hudson L, Poyser HR, Redpath N, Griffiths M, Steers G, Harris AL, Patel S, Berry J, Loader JA, Townsend RR, Daviet L, Legrain P, Parekh R, Terrett JA. 2003. Comprehensive proteomic analysis of breast cancer cell membranes reveals unique proteins with potential roles in clinical cancer. J Biol Chem 278:6482-6489.
7. Ahram M, Best CJ, Flaig MJ, Gillespie JW, Leiva IM, Chuaqui RF, Zhou G, Shu H, Duray PH, Linehan WM, Raffeld M, Ornstein DK, Zhao Y, Petricoin EF III, Emmert-Buck MR. 2002. Proteomic analysis of human prostate cancer. Mol Carcinog 33:9-15.
8. Alberti I, Barboro P, Barbesino M, Sanna P, Pisciotta L, Parodi S, Nicolo G, Boccardo F, Galli S, Patrone E, Balbi C. 2000. Changes in the expression of cytokeratins and nuclear matrix proteins are correlated with the level of differentiation in human prostate cancer. J Cell Biochem 79:471-485.
9. Ardekani AM, Liotta LA, Petricoin EF III. 2002. Clinical potential of proteomics in the diagnosis of ovarian cancer. Expert Rev Mol Diagn 2:312-320.
10. Arrell DK, Neverova I, Fraser H, Marban E, Van Eyk JE. 2001a. Proteomic analysis of pharmacologically preconditioned cardiomyocytes reveals novel phosphorylation of myosin light chain 1. Circ Res 89:480-487.
11. Arrell DK, Neverova I, Van Eyk JE. 2001b. Cardiovascular proteomics: Evolution and potential. Circ Res 88:763-773.
12. Asztalos BF, Roheim PS, Milani RL, Lefevre M, McNamara JR, Horvath KV, Schaefer EJ. 2000. Distribution of ApoA-I-containing HDL subpopulations in patients with coronary heart disease. Arterioscler Thromb Vasc Biol 20:2670-2676.
13. Balabanov S, Zimmermann U, Protzel C, Scharf C, Klebingat KJ, Walther R. 2001. Tumour-related enzyme alterations in the clear cell type of human renal cell carcinoma identified by two-dimensional gel electrophoresis. Eur J Biochem 268:5977-5980.
14. Bandara LR, Kennedy S. 2002. Toxicoproteomics - a new preclinical tool. Drug Discov Today 7:411-418.
15. Bandara LR, Kelly MD, Lock EA, Kennedy S. 2003. A correlation between a proteomic evaluation and conventional measurements in the assessment of renal proximal tubular toxicity. Toxicol Sci 73:195-206.
16. Bandera CA, Ye B, Mok SC. 2003. New technologies for the identification of markers for early detection of ovarian cancer. Curr Opin Obstet Gynecol 15:51-55.
17. Bandow JE, Brotz H, Leichert LI, Labischinski H, Hecker M. 2003. Proteomic approach to understanding antibiotic action. Antimicrob Agents Chemother 47:948-955.
18. Barcelo-Batllori S, Andre M, Servis C, Levy N, Takikawa O, Michetti P, Reymond M, Felley-Bosco E. 2002. Proteomic analysis of cytokine induced proteins in human intestinal epithelial cells: Implications for inflammatory bowel diseases. Proteomics 2:551-560.
19. Baruch A, Greenbaum D, Levy ET, Nielsen PA, Gilula NB, Kumar NM, Bogyo M. 2001. Defining a link between gap junction communication, proteolysis, and cataract formation. J Biol Chem 276:28999-29006.
20. Beck S, Sakurai T, Eustace BK, Beste G, Schier R, Rudert F, Jay DG. 2002. Fluorophore-assisted light inactivation: A high-throughput tool for direct target validation of proteins. Proteomics 2:247-255.
21. Beeley JA, Khoo KS. 1999. Salivary proteins in rheumatoid arthritis and Sjogren's syndrome: One-dimensional and two-dimensional electrophoretic studies. Electrophoresis 20:1652-1660.
22. Betts JC. 2002. Transcriptomics and proteomics: Tools for the identification of novel drug targets and vaccine candidates for tuberculosis. IUBMB Life 53:239-242.
23. Bienvenut WV, Deon C, Pasquarello C, Campbell JM, Sanchez JC, Vestal ML, Hochstrasser DF. 2002. Matrix-assisted laser desorption/ionization-tandem mass spectrometry with high resolution and sensitivity for identification and characterization of proteins. Proteomics 2:868-876.
24. Blass S, Specker C, Lakomek HJ, Schneider EM, Schwochau M. 1995. Novel 68 kDa autoantigen detected by rheumatoid arthritis specific antibodies. Ann Rheum Dis 54:355-360.
25. Bock JR, Gough DA. 2002. A new method to estimate ligand-receptor energetics. Mol Cell Proteomics 1:904-910.
26. Brichory F, Beer D, Le Naour F, Giordano T, Hanash S. 2001a. Proteomics-based identification of protein gene product 9.5 as a tumor antigen that induces a humoral immune response in lung cancer. Cancer Res 61:7908-7912.
27. Brichory FM, Misek DE, Yim AM, Krause MC, Giordano TJ, Beer DG, Hanash SM. 2001b. An immune response manifested by the common occurrence of annexins I and II autoantibodies and high circulating levels of IL-6 in lung cancer. Proc Natl Acad Sci USA 98:9824-9829.
28. Brunagel G, Schoen RE, Bauer AJ, Vietmeier BN, Getzenberg RH. 2002. Nuclear matrix protein alterations associated with colon cancer metastasis to the liver. Clin Cancer Res 8:3039-3045.
29. Bruneau JM, Maillet I, Tagat E, Legrand R, Supatto F, Fudali C, Caer JP, Labas V, Lecaque D, Hodgson J. 2003. Drug induced proteome changes in Candida albicans: Comparison of the effect of beta(1,3) glucan synthase inhibitors and two triazoles, fluconazole, and itraconazole. Proteomics 3:325-336.
30. Bruno ME, Borchers CH, Dial JM, Walker NJ, Hartis JE, Wetmore BA, Carl Barrett JC, Tomer KB, Merrick BA. 2002. Effects of TCDD upon IkappaB and IKK subunits localized in microsomes by proteomics. Arch Biochem Biophys 406:153-164.
31. Caron M, Imam-Sghiouar N, Poirier F, Le Caer JP, Labas V, Joubert-Caron R. 2002. Proteomic map and database of lymphoblastoid proteins. J Chromatogr B Anal Technol Biomed Life Sci 771:197-209.
32. Cash P, Argo E, Ford L, Lawrie L, McKenzie H. 1999. A proteomic analysis of erythromycin resistance in Streptococcus pneumoniae. Electrophoresis 20:2259-2268.
33. Celis JE, Gromov P. 2003. Proteomics in translational cancer research: Toward an integrated approach. Cancer Cell 3:9-15.
34. Celis JE, Ostergaard M, Basse B, Celis A, Lauridsen JB, Ratz GP, Andersen I, Hein B, Wolf H, Orntoft TF, Rasmussen HH. 1996. Loss of adipocyte-type fatty acid binding protein and other protein biomarkers is associated with progression of human bladder transitional cell carcinomas. Cancer Res 56:4782-4790.
35. Celis A, Rasmussen HH, Celis P, Basse B, Lauridsen JB, Ratz G, Hein B, Ostergaard M, Wolf H, Orntoft T, Celis JE. 1999a. Short-term culturing of low-grade superficial bladder transitional cell carcinomas leads to changes in the expression levels of several proteins involved in key cellular activities. Electrophoresis 20:355-361.
36. Celis JE, Celis P, Ostergaard M, Basse B, Lauridsen JB, Ratz G, Rasmussen HH, Orntoft TF, Hein B, Wolf H, Celis A. 1999b. Proteomics and immunohistochemistry define some of the steps involved in the squamous differentiation of the bladder transitional epithelium: A novel strategy for identifying metaplastic lesions. Cancer Res 59:3003-3009.
37. Celis JE, Ostergaard M, Rasmussen HH, Gromov P, Gromova I, Varmark H, Palsdottir H, Magnusson N, Andersen I, Basse B, Lauridsen JB, Ratz G, Wolf H, Orntoft TF, Celis P, Celis A. 1999c. A comprehensive protein resource for the study of bladder cancer: http://biobase.dk/cgi-bin/celis. Electrophoresis 20:300-309.
38. Celis JE, Wolf H, Ostergaard M. 1999d. Proteomic strategies in bladder cancer. IUBMB Life 48:19-23.
39. Celis JE, Wolf H, Ostergaard M. 2000. Bladder squamous cell carcinoma biomarkers derived from proteomics. Electrophoresis 21:2115-2121.
40. Chang CS, Chen LT, Yang JC, Lin JT, Chang KC, Wang JT. 1999. Isolation of a Helicobacter pylori protein, FldA, associated with mucosa-associated lymphoid tissue lymphoma of the stomach. Gastroenterology 117:82-88.
41. Chang JW, Jeon HB, Lee JH, Yoo JS, Chun JS, Kim JH, Yoo YJ. 2001. Augmented expression of peroxiredoxin I in lung cancer. Biochem Biophys Res Commun 289:507-512.
42. Charrier JP, Tournel C, Michel S, Comby S, Jolivet-Reynaud C, Passagot J, Dalbon P, Chautard D, Jolivet M. 2001. Differential diagnosis of prostate cancer and benign prostate hyperplasia using two-dimensional electrophoresis. Electrophoresis 22:1861-1866.
43. Chaurand P, DaGue BB, Pearsall RS, Threadgill DW, Caprioli RM. 2001a. Profiling proteins from azoxymethane-induced colon tumors at the molecular level by matrix-assisted laser desorption/ionization mass spectrometry. Proteomics 1:1320-1326.
44. Chaurand P, DaGue BB, Pearsall RS, Threadgill DW, Caprioli RM. 2001b. Profiling proteins from azoxymethane-induced colon tumors at the molecular level by matrix-assisted laser desorption/ionization mass spectrometry. Proteomics 1:1320-1326.
45. Chen G, Gharib TG, Huang CC, Thomas DG, Shedden KA, Taylor JM, Kardia SL, Misek DE, Giordano TJ, Iannettoni MD, Orringer MB, Hanash SM, Beer DG. 2002a. Proteomic analysis of lung adenocarcinoma: Identification of a highly expressed set of proteins in tumors. Clin Cancer Res 8:2298-2305.
46. Chen ST, Pan TL, Tsai YC, Huang CM. 2002b. Proteomics reveals protein profile changes in doxorubicin-treated MCF-7 human breast cancer cells. Cancer Lett 181:95-107.
47. Chen G, Wang H, Gharib TG, Huang CC, Thomas DG, Shedden KA, Kuick R, Taylor JM, Kardia SL, Misek DE, Giordano TJ, Iannettoni MD, Orringer MB, Hanash SM, Beer DG. 2003. Overexpression of oncoprotein 18 correlates with poor differentiation in lung adenocarcinomas. Mol Cell Proteomics 2:107-116.
48. Chevalier S, Macdonald N, Tonge R, Rayner S, Rowlinson R, Shaw J, Young J, Davison M, Roberts RA. 2000. Proteomic analysis of differential protein expression in primary hepatocytes induced by EGF, tumour necrosis factor alpha, or the peroxisome proliferator nafenopin. Eur J Biochem 267:4624-4634.
49. Chew EC, Liew CT, Wu S, Yang L, Yam HF, Wang SW, Lee SM, Wang ZH, Chew-Cheng SB. 1997. Electrophoretic analysis of nuclear matrix proteins in human hepatocellular carcinoma. Anticancer Res 17:3581-3585.
50. Cho CH, Nuttall ME. 2002. Emerging techniques for the discovery and validation of therapeutic targets for skeletal diseases. Expert Opin Ther Targets 6:679-689.
51. Cho SY, Park KS, Shim JE, Kwon MS, Joo KH, Lee WS, Chang J, Kim H, Chung HC, Kim HO, Paik YK. 2002. An integrated proteome database for two-dimensional electrophoresis data analysis and laboratory information management system. Proteomics 2:1104-1113.
52. Choong ML, Tan LK, Lo SL, Ren E-C, Ou K, Ong S-E, Liang RCMY, Seow TK, Chung MCM. 2001. An integrated approach in the discovery and characterization of a novel nuclear protein over-expressed in liver and pancreatic tumors. FEBS Lett 496:109-116.
53. Chu R, Zhang W, Lim H, Yeldandi AV, Herring C, Brumfield L, Reddy JK, Davison M. 2002. Profiling of acyl-CoA oxidase-deficient and peroxisome proliferator Wy14,643-treated mouse liver protein by surface-enhanced laser desorption/ionization ProteinChip biology system. Gene Expr 10:165-177.
54. Cole AR, Ji H, Simpson RJ. 2000. Proteomic analysis of colonic crypts from normal, multiple intestinal neoplasia, and p53-null mice: A comparison with colonic polyps. Electrophoresis 21:1772-1781.
55. Coombes BK, Johnson DL, Mahony JB. 2002. Strategic targeting of essential host-pathogen interactions in chlamydial disease. Curr Drug Targets Infect Disord 2:201-216.
56. Corbett JM, Why HJ, Wheeler CH, Richardson PJ, Archard LC, Yacoub MH, Dunn MJ. 1998. Cardiac protein abnormalities in dilated cardiomyopathy detected by two-dimensional polyacrylamide gel electrophoresis. Electrophoresis 19:2031-2042.
57. Dayal B, Ertel NH. 2002. ProteinChip technology: A new and facile method for the identification and measurement of high-density lipoproteins apoA-I and apoA-II and their glycosylated products in patients with diabetes and cardiovascular disease. J Proteome Res 1:375-380.
58. Duche O, Tremoulet F, Namane A, Labadie J. 2002. A proteomic analysis of the salt stress response of Listeria monocytogenes. FEMS Microbiol Lett 215:183-188.
59. Dunn MJ. 2000. Studying heart disease using the proteomic approach. Drug Discov Today 5:76-84.
60. Dunn MJ, Corbett JM, Wheeler CH. 1997. HSC-2DPAGE and the two-dimensional gel electrophoresis database of dog heart proteins. Electrophoresis 18:2795-2802.
61. Edmondson RD, Vondriska TM, Biederman KJ, Zhang J, Jones RC, Zheng Y, Allen DL, Xiu JX, Cardwell EM, Pisano MR, Ping P. 2002. Protein kinase C epsilon signaling complexes include metabolism- and transcription/translation-related proteins: Complimentary separation techniques with LC/MS/MS. Mol Cell Proteomics 1:421-433.
62. Edvardsson U, Alexandersson M, Brockenhuus vL, Nystrom AC, Ljung B, Nilsson F, Dahllof B. 1999. A proteome analysis of livers from obese (ob/ob) mice treated with the peroxisome proliferator WY14,643. Electrophoresis 20:935-942.
63. Enroth H, Akerlund T, Sillen A, Engstrand L. 2000. Clustering of clinical strains of Helicobacter pylori analyzed by two-dimensional gel electrophoresis. Clin Diagn Lab Immunol 7:301-306.
64. Evans G, Wheeler CH, Corbett JM, Dunn MJ. 1997. Construction of HSC-2DPAGE: A two-dimensional gel electrophoresis database of heart proteins. Electrophoresis 18:471-479.
65. Faleiro L, Kobayashi R, Fearnhead H, Lazebnik Y. 1997. Multiple species of CPP32 and Mch2 are the major active caspases present in apoptotic cells. EMBO J 16:2271-2281.
66. Fountoulakis M, Berndt P, Boelsterli UA, Crameri F, Winter M, Albertini S, Suter L. 2000. Two-dimensional database of mouse liver proteins: Changes in hepatic protein levels following treatment with acetaminophen or its nontoxic regioisomer 3-acetamidophenol. Electrophoresis 21:2148-2161.
67. Franzen B, Linder S, Alaiya AA, Eriksson E, Uruy K, Hirano T, Okuzawa K, Auer G. 1996. Analysis of polypeptide expression in benign and malignant human breast lesions: Down-regulation of cytokeratins. Br J Cancer 74:1632-1638.
68. Friso G, Kaiser L, Raud J, Wikstrom L. 2001. Differential protein expression in rat trigeminal ganglia during inflammation. Proteomics 1:397-408.
69. Gharib TG, Chen G, Wang H, Huang CC, Prescott MS, Shedden K, Misek DE, Thomas DG, Giordano TJ, Taylor JM, Kardia S, Yee J, Orringer MB, Hanash S, Beer DG. 2002. Proteomic analysis of cytokeratin isoforms uncovers association with survival in lung adenocarcinoma. Neoplasia 4:440-448.
70. Gianazza E, Eberini I, Villa P, Fratelli M, Pinna C, Wait R, Gemeiner M, Miller I. 2002. Monitoring the effects of drug treatment in rat models of disease by serum protein analysis. J Chromatogr B Analyt Technol Biomed Life Sci 771:107-130.
71. Graves PR, Haystead TA. 2002. Molecular biologist's guide to proteomics. Microbiol Mol Biol Rev 66:39-63.
72. Graves PR, Kwiek JJ, Fadden P, Ray R, Hardeman K, Coley AM, Foley M, Haystead TA. 2002. Discovery of novel targets of quinoline drugs in the human purine binding proteome. Mol Pharmacol 62:1364-1372.
73. Greenbaum DC, Baruch A, Grainger M, Bozdech Z, Medzihradszky KF, Engel J, DeRisi J, Holder AA, Bogyo M. 2002. A role for the protease falcipain 1 in host cell invasion by the human malaria parasite. Science 298:2002-2006.
74. Gromova I, Gromov P, Wolf H, Celis JE. 1998. Protein abundancy and mRNA levels of the adipocyte-type fatty acid binding protein correlate in non-invasive and invasive bladder transitional cell carcinomas. Int J Oncol 13:379-383.
75. Gururaja TL, Li W, Payan DG, Anderson DC. 2003. Utility of peptide-protein affinity complexes in proteomics: Identification of interaction partners of a tumor suppressor peptide. J Pept Res 61:163-176.
76. Gygi SP, Rist B, Gerber SA, Turecek F, Gelb MH, Aebersold R. 1999. Quantitative analysis of complex protein mixtures using isotope-coded affinity tags. Nat Biotechnol 17:994-999.
77. Ha GH, Lee SU, Kang DG, Ha NY, Kim SH, Kim J, Bae JM, Kim JW, Lee CW. 2002. Proteome analysis of human stomach tissue: Separation of soluble proteins by two-dimensional polyacrylamide gel electrophoresis and identification by mass spectrometry. Electrophoresis 23:2513-2524.
78. Haas G, Karaali G, Ebermayer K, Metzger WG, Lamer S, Zimny-Arndt U, Diescher S, Goebel UB, Vogt K, Roznowski AB, Wiedenmann BJ, Meyer TF, Aebischer T, Jungblut PR. 2002. Immunoproteomics of Helicobacter pylori infection and relation to gastric disease. Proteomics 2:313-324.
79. Hanash SM. 2001. Global profiling of gene expression in cancer using genomics and proteomics. Curr Opin Mol Ther 3:538-545.
80. Hanash S, Brichory F, Beer D. 2001. A proteomic approach to the identification of lung cancer markers. Dis Markers 17:295-300.
81. Hanash SM, Madoz-Gurpide J, Misek DE. 2002. Identification of novel targets for cancer therapy using expression proteomics. Leukemia 16:478-485.
82. He QY, Yip TT, Li M, Chiu JF. 2003a. Proteomic analyses of arsenic-induced cell transformation with SELDI-TOF ProteinChip(R) technology. J Cell Biochem 88:1-8.
83. He QY, Lau GKK, Zhou Y, Yuen ST, Lin MC, Kung HF, Chiu JF. 2003b. Serum biomarkers of hepatitis B virus infected liver inflammation: A proteomic study. Proteomics 3:666-674.
84. Heegaard NH, Larsen MR, Muncrief T, Wiik A, Roepstorff P. 2000. Heterogeneous nuclear ribonucleoproteins C1/ C2 identified as autoantigens by biochemical and mass spectrometric methods. Arthritis Res 2:407-414.
85. Heinke MY, Wheeler CH, Chang D, Einstein R, Drake-Holland A, Dunn MJ, dos Remedios CG. 1998. Protein changes observed in pacing-induced heart failure using two-dimensional electrophoresis. Electrophoresis 19:2021-2030.
86. Heinke MY, Wheeler CH, Yan JX, Amin V, Chang D, Einstein R, Dunn MJ, dos Remedios CG. 1999. Changes in myocardial protein expression in pacing-induced canine heart failure. Electrophoresis 20:2086-2093.
87. Hellmold H, Nilsson CB, Schuppe-Koistinen I, Kenne K, Warngard L. 2002. Identification of end points relevant to detection of potentially adverse drug reactions. Toxicol Lett 127:239-243.
88. Hendrickson RC, Douglass JF, Reynolds LD, McNeill PD, Carter D, Reed SG, Houghton RL. 2000. Mass spectrometric identification of mtb81, a novel serological marker for tuberculosis. J Clin Microbiol 38:2354-2361.
89. Herman EH, Zhang J, Rifai N, Lipshultz SE, Hasinoff BB, Chadwick DP, Knapton A, Chai J, Ferrans VJ. 2001. The use of serum levels of cardiac troponin T to compare the protective activity of dexrazoxane against doxorubicin- and mitoxantrone-induced cardiotoxicity. Cancer Chemother Pharmacol 48:297-304.
90. Hoffmann P, Ji H, Moritz RL, Connolly LM, Frecklington DF, Layton MJ, Eddes JS, Simpson RJ. 2001. Continuous free-flow electrophoresis separation of cytosolic proteins from the human colon carcinoma cell line LIM 1215: A non two-dimensional gel electrophoresis-based proteome analysis strategy. Proteomics 1:807-818.
91. Hondermarck H, Vercoutter-Edouart AS, Revillion F, Lemoine J, Yazidi-Belkoura I, Nurcombe V, Peyrat JP. 2001. Proteomics of breast cancer for marker discovery and signal pathway profiling. Proteomics 1:1216-1232.
92. Hueber W, Utz PJ, Steinman L, Robinson WH. 2002. Autoantibody profiling for the study and treatment of autoimmune disease. Arthritis Res 4:290-295.
93. Jager D, Jungblut PR, Muller-Werdan U. 2002. Separation and identification of human heart proteins. J Chromatogr B Anal Technol Biomed Life Sci 771:131-153.
94. Jeffery DA, Bogyo M. 2003. Chemical proteomics and its application to drug discovery. Curr Opin Biotechnol 14:87-95.
95. Jessani N, Liu Y, Humphrey M, Cravatt BF. 2002. Enzyme activity profiles of the secreted and membrane proteome that depict cancer cell invasiveness. Proc Natl Acad Sci USA 99:10335-10340.
96. Jiang L, Tsubakihara M, Heinke MY, Yao M, Dunn MJ, Phillips W, dos Remedios CG, Nosworthy NJ. 2001. Heart failure and apoptosis: Electrophoretic methods support data from micro- and macro-arrays. A critical review of genomics and proteomics. Proteomics 1:1481-1488.
97. Jones MB, Krutzsch H, Shu H, Zhao Y, Liotta LA, Kohn EC, Petricoin EF III. 2002. Proteomic analysis and identification of new biomarkers and therapeutic targets for invasive ovarian cancer. Proteomics 2:76-84.
98. Jr GW, Jr., Cazares LH, Leung SM, Nasim S, Adam BL, Yip TT, Schellhammer PF, Gong L, Vlahou A. 1999. Proteinchip(R) surface enhanced laser desorption/ionization (SELDI) mass spectrometry: A novel protein biochip technology for detection of prostate cancer biomarkers in complex protein mixtures. Prostate Cancer Prostatic Dis 2:264-276.
99. Kanamoto T, Hellman U, Heldin CH, Souchelnytskyi S. 2002. Functional proteomics of transforming growth factor-beta1-stimulated Mv1Lu epithelial cells: Rad51 as a target of TGFbeta1-dependent regulation of DNA repair. EMBO J 21:1219-1230.
100. Keesee SK, Meneghini MD, Szaro RP, Wu YJ. 1994. Nuclear matrix proteins in human colon cancer. Proc Natl Acad Sci USA 91:1913-1916.
101. Kennedy S. 2002. The role of proteomics in toxicology: Identification of biomarkers of toxicity by protein expression analysis. Biomarkers 7:269-290.
102. Kidd D, Liu Y, Cravatt BF. 2001. Profiling serine hydrolase activities in complex proteomes. Biochemistry 40:4005-4015.
103. Klade CS, Voss T, Krystek E, Ahorn H, Zatloukal K, Pummer K, Adolf GR. 2001. Identification of tumor antigens in renal cell carcinoma by serological proteome analysis. Proteomics 1:890-898.
104. Kovarova H, Halada P, Man P, Dzubak P, Hajduch M. 2002. Application of proteomics in the search for novel proteins associated with the anti-cancer effect of the synthetic cyclin-dependent kinases inhibitor, bohemine. Technol Cancer Res Treat 1:247-256.
105. Krieg RC, Paweletz CP, Liotta LA, Petricoin EF III. 2002. Clinical proteomics for cancer biomarker discovery and therapeutic targeting. Technol Cancer Res Treat 1:263-272.
106. Kuerer HM, Goldknopf IL, Fritsche H, Krishnamurthy S, Sheta EA, Hunt KK. 2002. Identification of distinct protein expression patterns in bilateral matched pair breast ductal fluid specimens from women with unilateral invasive breast carcinoma. High-throughput biomarker discovery. Cancer 95:2276-2282.
107. Labugger R, McDonough JL, Neverova I, Van Eyk JE. 2002. Solubilization, two-dimensional separation, and detection of the cardiac myofilament protein troponin T. Proteomics 2:673-678.
108. Lakshmanan Y, Subong EN, Partin AW. 1998. Differential nuclear matrix protein expression in prostate cancers: Correlation with pathologic stage. J Urol 159:1354-1358.
109. Le Naour F, Misek DE, Krause MC, Deneux L, Giordano TJ, Scholl S, Hanash SM. 2001. Proteomics-based identification of RS/DJ-1 as a novel circulating tumor antigen in breast cancer. Clin Cancer Res 7:3328-3335.
110. Le Naour F, Brichory F, Misek DE, Brechot C, Hanash SM, Beretta L. 2002. A distinct repertoire of autoantibodies in hepatocellular carcinoma identified by proteomic analysis. Mol Cell Proteomics 1:197-203.
111. Lewis TS, Hunt JB, Aveline LD, Jonscher KR, Louie DF, Yeh JM, Nahreini TS, Resing KA, Ahn NG. 2000. Identification of novel MAP kinase pathway signaling targets by functional proteomics and mass spectrometry. Mol Cell 6:1343-1354.
112. Li XP, Pleissner KP, Scheler C, Regitz-Zagrosek V, Salnikow J, Jungblut PR. 1999. A two-dimensional electrophoresis database of rat heart proteins. Electrophoresis 20:891-897.
113. Li J, Zhang Z, Rosenzweig J, Wang YY, Chan DW. 2002. Proteomics and bioinformatics approaches for identification of serum biomarkers to detect breast cancer. Clin Chem 48:1296-1304.
114. Liang RC, Neo JC, Ling LS, San TG, Keong ST, Chung MC. 2002. Proteome database of hepatocellular carcinoma. J Chromatogr B Anal Technol Biomed Life Sci 771:303-328.
115. Lichtenfels R, Kellner R, Bukur J, Beck J, Brenner W, Ackermann A, Seliger B. 2002. Heat shock protein expression and anti-heat shock protein reactivity in renal cell carcinoma. Proteomics 2:561-570.
116. Lim SO, Park S-J, Kim W, Park SG, Kim HJ, Kim YI, Sohn TS, Noh JH, Jung G. 2002. Proteome analysis of hepatocellular carcinoma. Biochem Biophys Res Commun 291:1031-1037.
117. Lind C, Gerdes R, Hamnell Y, Schuppe-Koistinen I, von Lowenhielm HB, Holmgren A, Cotgreave IA. 2002. Identification of S-glutathionylated cellular proteins during oxidative stress and constitutive metabolism by affinity purification and proteomic analysis. Arch Biochem Biophys 406:229-240.
118. Liotta LA, Petricoin EF III, Ardekani AM, Hitt BA, Levine PJ, Fusaro VA, Steinberg SM, Mills GB, Simone C, Fishman DA, Kohn EC. 2003. General keynote: Proteomic patterns in sera serve as biomarkers of ovarian cancer. Gynecol Oncol 88:S25-S28.
119. Luftner D, Possinger K. 2002. Nuclear matrix proteins as biomarkers for breast cancer. Expert Rev Mol Diagn 2:23-31.
120. Macdonald N, Chevalier S, Tonge R, Davison M, Rowlinson R, Young J, Rayner S, Roberts R. 2001. Quantitative proteomic analysis of mouse liver response to the peroxisome proliferator diethylhexylphthalate (DEHP). Arch Toxicol 75:415-424.
121. Macri J, Rapundalo ST. 2001. Application of proteomics to the study of cardiovascular biology. Trends Cardiovasc Med 11:66-75.
122. Madoz-Gurpide J, Wang H, Misek DE, Brichory F, Hanash SM. 2001. Protein based microarrays: A tool for probing the proteome of cancer cells and tissues. Proteomics 1:1279-1287.
123. Maguire PB, Wynne KJ, Harney DF, O'Donoghue NM, Stephens G, Fitzgerald DJ. 2002. Identification of the phosphotyrosine proteome from thrombin activated platelets. Proteomics 2:642-648.
124. Man WJ, White IR, Bryant D, Bugelski P, Camilleri P, Cutler P, Heald G, Lord PG, Wood J, Kramer K. 2002. Protein expression analysis of drug-mediated hepatotoxicity in the Sprague-Dawley rat. Proteomics 2:1577-1585.
125. Mannes AJ, Martin BM, Yang HY, Keller JM, Lewin S, Gaiser RR, Iadarola MJ. 2003. Cystatin C as a cerebrospinal fluid biomarker for pain in humans. Pain 102:251-256.
126. McCormack AL, Schieltz DM, Goode B, Yang S, Barnes G, Drubin D, Yates JR III. 1997. Direct analysis and identification of proteins in mixtures by LC/MS/MS and database searching at the low-femtomole level. Anal Chem 69:767-776.
127. McDonough JL, Neverova I, Van Eyk JE. 2002. Proteomic analysis of human biopsy samples by single two-dimensional electrophoresis: Coomassie, silver, mass spectrometry, and Western blotting. Proteomics 2:978-987.
128. Meister W. 2002. Pharmacogenomics/pharmacoproteomics Europe. Pharmacogenomics 3:449-452.
129. Mitsiades N, Mitsiades CS, Richardson PG, Poulaki V, Tai YT, Chauhan D, Fanourakis G, Gu X, Bailey C, Joseph M, Libermann TA, Schlossman R, Munshi NC, Hideshima T, Anderson KC. 2003. The proteasome inhibitor PS-341 potentiates sensitivity of multiple myeloma cells to conventional chemotherapeutic agents: Therapeutic applications. Blood 101:2377-2380.
130. Muller EC, Thiede B, Zimny-Arndt U, Scheler C, Prehm J, Muller-Werdan U, Wittmann-Liebold B, Otto A, Jungblut P. 1996. High-performance human myocardial two-dimensional electrophoresis database: Edition 1996. Electrophoresis 17:1700-1712.
131. Naour FL, Brichory F, Beretta L, Hanash SM. 2002. Identification of tumor-associated antigens using proteomics. Technol Cancer Res Treat 1:257-262.
132. Neverova I, Van Eyk JE. 2002. Application of reversed phase high performance liquid chromatography for subproteomic analysis of cardiac muscle. Proteomics 2:22-31.
133. Newsholme SJ, Maleeff BF, Steiner S, Anderson NL, Schwartz LW. 2000. Two-dimensional electrophoresis of liver proteins: Characterization of a drug-induced hepatomegaly in rats. Electrophoresis 21:2122-2128.
134. O'Neill EE, Brock CJ, von Kriegsheim AF, Pearce AC, Dwek RA, Watson SP, Hebestreit HF. 2002. Towards complete analysis of the platelet proteome. Proteomics 2:288-305.
135. Oh JM, Brichory F, Puravs E, Kuick R, Wood C, Rouillard JM, Tra J, Kardia S, Beer D, Hanash S. 2001. A database of protein expression in lung cancer. Proteomics 1:1303-1319.
136. Ornstein DK, Gillespie JW, Paweletz CP, Duray PH, Herring J, Vocke CD, Topalian SL, Bostwick DG, Linehan WM, Petricoin EF III, Emmert-Buck MR. 2000. Proteomic analysis of laser capture microdissected human prostate cancer and in vitro prostate cell lines. Electrophoresis 21:2235-2242.
137. Ostergaard M, Rasmussen HH, Nielsen HV, Vorum H, Orntoft TF, Wolf H, Celis JE. 1997. Proteome profiling of bladder squamous cell carcinomas: Identification of markers that define their degree of differentiation. Cancer Res 57:4111-4117.
138. Ostergaard M, Wolf H, Orntoft TF, Celis JE. 1999. Psoriasin (S100A7): A putative urinary marker for the follow-up of patients with bladder squamous cell carcinomas. Electrophoresis 20:349-354.
139. Otto A, Thiede B, Muller EC, Scheler C, Wittmann-Liebold B, Jungblut P. 1996. Identification of human myocardial proteins separated by two-dimensional electrophoresis using an effective sample preparation for mass spectrometry. Electrophoresis 17:1643-1650.
140. Owens J. 2001. Topological proteomics: A new approach to drug discovery. Drug Discov Today 6:1081-1082.
141. Pankuweit S, Portig I, Lottspeich F, Maisch B. 1997. Autoantibodies in sera of patients with myocarditis: Characterization of the corresponding proteins by isoelectric focusing and N-terminal sequence analysis. J Mol Cell Cardiol 29:77-84.
142. Park K-S, Che SY, Kim H, Paik Y-K. 2002. Proteomic alterations of the variants of human aldehyde dehydrogenase isozymes correlate with hepatocellular carcinoma. Int J Cancer 97:261-265.
143. Patel V, Leethanakul C, Gutkind JS. 2001. New approaches to the understanding of the molecular basis of oral cancer. Crit Rev Oral Biol Med 12:55-63.
144. Patterson S. 2002. Selecting targets for therapeutic validation through differential protein expression using chromatography-mass spectrometry. Bioinformatics 18(Suppl 2):S181.
145. Paweletz CP, Liotta LA, Petricoin EF III. 2001a. New technologies for biomarker analysis of prostate cancer progression: Laser capture microdissection and tissue proteomics. Urology 57:160-163.
146. Paweletz CP, Trock B, Pennanen M, Tsangaris T, Magnant C, Liotta LA, Petricoin EF III. 2001b. Proteomic patterns of nipple aspirate fluids obtained by SELDI-TOF: Potential for new biomarkers to aid in the diagnosis of breast cancer. Dis Markers 17:301-307.
147. Peng J, Gygi SP. 2001. Proteomics: The move to mixtures. J Mass Spectrom 36:1083-1091.
148. Petricoin EF, Ardekani AM, Hitt BA, Levine PJ, Fusaro VA, Steinberg SM, Mills GB, Simone C, Fishman DA, Kohn EC, Liotta LA. 2002a. Use of proteomic patterns in serum to identify ovarian cancer. Lancet 359:572-577.
149. Petricoin EF III, Ornstein DK, Paweletz CP, Ardekani A, Hackett PS, Hitt BA, Velassco A, Trucco C, Wiegand L, Wood K, Simone CB, Levine PJ, Linehan WM, Emmert-Buck MR, Steinberg SM, Kohn EC, Liotta LA. 2002b. Serum proteomic patterns for detection of prostate cancer. J Natl Cancer Inst 94:1576-1578.
150. Pleissner KP, Sander S, Oswald H, Regitz-Zagrosek V, Fleck E. 1996. The construction of the world wide web-accessible myocardial two-dimensional gel electrophoresis protein database "HEART-2DPAGE": A practical approach. Electrophoresis 17:1386-1392.
151. Pleissner KP, Soding P, Sander S, Oswald H, Neuss M, Regitz-Zagrosek V, Fleck E. 1997. Dilated cardiomyopathy-associated proteins and their presentation in a WWW-accessible two-dimensional gel protein database. Electrophoresis 18:802-808.
152. Pleissner KP, Regitz-Zagrosek V, Krudewagen B, Trenkner J, Hocher B, Fleck E. 1998. Effects of renovascular hypertension on myocardial protein patterns: Analysis by computer-assisted two-dimensional gel electrophoresis. Electrophoresis 19:2043-2050.
153. Pohlner K, Portig I, Pankuweit S, Lottspeich F, Maisch B. 1997. Identification of mitochondrial antigens recognized by antibodies in sera of patients with idiopathic dilated cardiomyopathy by two-dimensional gel electrophoresis and protein sequencing. Am J Cardiol 80:1040-1045.
154. Poirier F, Pontet M, Labas V, Le Caer JP, Sghiouar-Imam N, Raphael M, Caron M, Joubert-Caron R. 2001. Two-dimensional database of a Burkitt lymphoma cell line (DG 75) proteins: Protein pattern changes following treatment with 5′-azycytidine. Electrophoresis 22:1867-1877.
155. Prasannan L, Misek DE, Hinderer R, Michon J, Geiger JD, Hanash SM. 2000. Identification of beta-tubulin isoforms as tumor antigens in neuroblastoma. Clin Cancer Res 6:3949-3956.
156. Qian Y, Sensibar JA, Zelner DJ, Schaeffer AJ, Finlay JA, Rittenhouse HG, Lee C. 1997. Two-dimensional gel electrophoresis detects prostate-specific antigen-alpha1-antichymotrypsin complex in serum but not in prostatic fluid. Clin Chem 43:352-359.
157. Qu Y, Adam BL, Yasui Y, Ward MD, Cazares LH, Schellhammer PF, Feng Z, Semmes OJ, Wright GL, Jr. 2002. Boosted decision tree analysis of surface-enhanced laser desorption/ionization mass spectral serum profiles discriminates prostate cancer from noncancer patients. Clin Chem 48:1835-1843.
158. Randic M, Basak SC. 2002. A comparative study of proteomics maps using graph theoretical biodescriptors. J Chem Inf Comput Sci 42:983-992.
159. Rasmussen HH, Orntoft TF, Wolf H, Celis JE. 1996. Towards a comprehensive database of proteins from the urine of patients with bladder cancer. J Urol 155:2113-2119.
160. Rubenwolf S, Niewohner J, Meyer E, Petit-Frere C, Rudert F, Hoffmann PR, Ilag LL. 2002. Functional proteomics using chromophore-assisted laser inactivation. Proteomics 2:241-246.
161. Ruepp SU, Tonge RP, Shaw J, Wallis N, Pognan F. 2002. Genomics and proteomics analysis of acetaminophen toxicity in mouse liver. Toxicol Sci 65:135-150.
162. Sanchez JC, Converset V, Nolan A, Schmid G, Wang S, Heller M, Sennitt MV, Hochstrasser DF, Cawthorne MA. 2002. Effect of rosiglitazone on the differential expression of diabetes-associated proteins in pancreatic islets of C57B1/6 lep/lep mice. Mol Cell Proteomics 1:509-516.
163. Sarto C, Frutiger S, Cappellano F, Sanchez JC, Doro G, Catanzaro F, Hughes GJ, Hochstrasser DF, Mocarelli P. 1999. Modified expression of plasma glutathione peroxidase and manganese superoxide dismutase in human renal cell carcinoma. Electrophoresis 20:3458-3466.
164. Saulot V, Vittecoq O, Charlionet R, Fardellone P, Lange C, Marvin L, Machour N, Le L, Loet X, Gilbert D, Tron F. 2002. Presence of autoantibodies to the glycolytic enzyme alpha-enolase in sera from patients with early rheumatoid arthritis. Arthritis Rheum 46:1196-1201.
165. Scheler C, Muller EC, Stahl J, Muller-Werdan U, Salnikow J, Jungblut P. 1997a. Identification and characterization of heat shock protein 27 protein species in human myocardial two-dimensional electrophoresis patterns. Electrophoresis 18:2823-2831.
166. Scheler C, Muller EC, Stahl J, Muller-Werdan U, Salnikow J, Jungblut P. 1997b. Identification and characterization of heat shock protein 27 protein species in human myocardial two-dimensional electrophoresis patterns. Electrophoresis 18:2823-2831.
167. Scheler C, Li XP, Salnikow J, Dunn MJ, Jungblut PR. 1999. Comparison of two-dimensional electrophoresis patterns of heat shock protein Hsp27 species in normal and cardiomyopathic hearts. Electrophoresis 20:3623-3628.
168. Schwertz H, Langin T, Platsch H, Richert J, Bomm S, Schmidt M, Hillen H, Blaschke G, Meyer J, Darius H, Buerke M. 2002. Two-dimensional analysis of myocardial protein expression following myocardial ischemia and reperfusion in rabbits. Proteomics 2:988-995.
169. Seow TK, Ong SE, Liang RC, Ren EC, Chan L, Ou K, Chung MC. 2000. Two-dimensional electrophoresis map of the human hepatocellular carcinoma cell line, HCC-M, and identification of the separated proteins by mass spectrometry. Electrophoresis 21:1787-1813.
170. Seow TK, Liang RC, Leow CK, Chung MC. 2001. Hepatocellular carcinoma: From beside to proteomics. Proteomics 1:1249-1263.
171. Shalhoub P, Kern S, Girard S, Beretta L. 2001. Proteomic-based approach for the identification of tumor markers associated with hepatocellular carcinoma. Dis Markers 17:217-223.
172. Simpson RJ, Connolly LM, Eddes JS, Pereira JJ, Moritz RL, Reid GE. 2000. Proteomic analysis of the human colon carcinoma cell line (LIM 1215): Development of a membrane protein database. Electrophoresis 21:1707-1732.
173. Singh VK, Jayaswal RK, Wilkinson BJ. 2001. Cell wall-active antibiotic induced proteins of Staphylococcus aureus identified using a proteomic approach. FEMS Microbiol Lett 199:79-84.
174. Sinha P, Hutter G, Kottgen E, Dietel M, Schadendorf D, Lage H. 1998. Increased expression of annexin I and thioredoxin detected by two-dimensional gel electrophoresis of drug resistant human stomach cancer cells. J Biochem Biophys Methods 37:105-116.
175. Sinha P, Poland J, Schnolzer M, Celis JE, Lage H. 2001. Characterization of the differential protein expression associated with thermoresistance in human gastric carcinoma cell lines. Electrophoresis 22:2990-3000.
176. Sironi L, Tremoli E, Miller I, Guerrini U, Calvio AM, Eberini I, Gemeiner M, Asdente M, Paoletti R, Gianazza E. 2001. Acute-phase proteins before cerebral ischemia in stroke-prone rats: Identification by proteomics. Stroke 32:753-760.
177. Smith MA, Bains SK, Betts JC, Choy EH, Zanders ED. 2001. Use of two-dimensional gel electrophoresis to measure changes in synovial fluid proteins from patients with rheumatoid arthritis treated with antibody to CD4. Clin Diagn Lab Immunol 8:105-111.
178. Spencer DI, Robson L, Purdy D, Whitelegg NR, Michael NP, Bhatia J, Sharma SK, Rees AR, Minton NP, Begent RH, Chester KA. 2002. A strategy for mapping and neutralizing conformational immunogenic sites on protein therapeutics. Proteomics 2:271-279.
179. Srisomsap C, Subhasitanont P, Otto A, Mueller EC, Punyarit P, Wittmann-Liebold B, Svasti J. 2002. Detection of cathepsin B up-regulation in neoplastic thyroid tissues by proteomic analysis. Proteomics 2:706-712.
180. Stancato LF, Petricoin EF III. 2001. Fingerprinting of signal transduction pathways using a combination of anti-phosphotyrosine immunoprecipitations and two-dimensional polyacrylamide gel electrophoresis. Electrophoresis 22:2120-2124.
181. Steel LF, Mattu TS, Mehta A, Hebestreit H, Dwek R, Evans AA, London WT, Block T. 2001. A proteomic approach for the discovery of early detection markers of hepatocellular carcinoma. Dis Markers 17:179-189.
182. Steiner S, Anderson NL. 2000. Expression profiling in toxicology - potentials and limitations. Toxicol Lett 112-113:467-471.
183. Steiner S, Gatlin CL, Lennon JJ, McGrath AM, Aponte AM, Makusky AJ, Rohrs MC, Anderson NL. 2000. Proteomics to display lovastatin-induced protein and pathway regulation in rat liver. Electrophoresis 21:2129-2137.
184. Storm SM, Khawaja XZ. 1999. Probing for drug-induced multiplex signal transduction pathways using high resolution two-dimensional gel electrophoresis: Application to beta-adrenoceptor stimulation in the rat C6 glioma cell. Brain Res Mol Brain Res 71:50-60.
185. Stulik J, Hernychova L, Porkertova S, Knizek J, Macela A, Bures J, Jandik P, Langridge JI, Jungblut PR. 2001. Proteome study of colorectal carcinogenesis. Electrophoresis 22:3019-3025.
186. Tan S, Seow TK, Liang RC, Koh S, Lee CP, Chung MC, Hooi SC. 2002. Proteome analysis of butyrate-treated human colon cancer cells (HT-29). Int J Cancer 98:523-531.
187. Tang H, Peng T, Wong-Staal F. 2002. Novel technologies for studying virus-host interaction and discovering new drug targets for HCV and HIV. Curr Opin Pharmacol 2:541-547.
188. i ratio in cultured vascular smooth muscle cells. Circ Res 91:915-922.
189. Toledo-Sherman LM, Chen D. 2002. High-throughput virtual screening for drug discovery in parallel. Curr Opin Drug Discov Dev 5:414-421.
190. Tomlinson AJ, Hincapie M, Morris GE, Chicz RM. 2002. Global proteome analysis of a human gastric carcinoma. Electrophoresis 23:3233-3240.
191. Tontsch D, Pankuweit S, Maisch B. 2000. Autoantibodies in the sera of patients with rheumatic heart disease: Characterization of myocardial antigens by two-dimensional immunoblotting and N-terminal sequence analysis. Clin Exp Immunol 121:270-274.
192. Van Eyk JE. 2001. Proteomics: Unraveling the complexity of heart disease and striving to change cardiology. Curr Opin Mol Ther 3:546-553.
193. VerBerkmoes NC, Bundy JL, Hauser L, Asano KG, Razumovskaya J, Larimer F, Hettich RL, Stephenson JL, Jr. 2002. Integrating "top-down" and "bottom-up" mass spectrometric approaches for proteomic analysis of Shewanella oneidensis. J Proteome Res 1:239-252.
194. Vlahou A, Schellhammer PF, Mendrinos S, Patel K, Kondylis FI, Gong L, Nasim S, Wright JG, Jr. 2001. Development of a novel proteomic approach for the detection of transitional cell carcinoma of the bladder in urine. Am J Pathol 158:1491-1502.
195. Voss T, Ahorn H, Haberl P, Dohner H, Wilgenbus K. 2001. Correlation of clinical data with proteomics profiles in 24 patients with B-cell chronic lymphocytic leukemia. Int J Cancer 91:180-186.
196. Wan J, Wang J, Cheng H, Yu Y, Xing G, Oiu Z, Qian X, He F. 2001. Proteomic analysis of apoptosis initiation induced by all-trans-retinoic acid in human acute promyelocytic leukemia cells. Electrophoresis 22:3026-3037.
197. Wang H, Hanash SM. 2002. Contributions of proteome profiling to the molecular analysis of cancer. Technol Cancer Res Treat 1:237-246.
198. Wang YY, Khoo KH, Chen ST, Lin CC, Wong CH, Lin CH. 2002. Studies on the immuno-modulating and antitumor activities of Ganoderma lucidum (Reishi) polysaccharides: Functional and proteomic analyses of a fucose-containing glycoprotein fraction responsible for the activities. Bioorg Med Chem 10:1057-1062.
199. Wasinger VC, Cordwell SJ, Cerpa-Poljak A, Yan JX, Gooley AA, Wilkins MR, Duncan MW, Harris R, Williams KL, Humphery-Smith I. 1995. Progress with gene-product mapping of the Mollicutes: Mycoplasma genitalium. Electrophoresis 16:1090-1094.
200. Weekes J, Wheeler CH, Yan JX, Weil J, Eschenhagen T, Scholtysik G, Dunn MJ. 1999. Bovine dilated cardiomyopathy: Proteomic analysis of an animal model of human dilated cardiomyopathy. Electrophoresis 20:898-906.
201. Weekes J, Watson RR, Dunn MJ. 2003. Murine retrovirus infection and the effect of chronic alcohol consumption: Proteomic analysis of cardiac protein expression. Alcohol Alcohol 38:103-108.
202. Wellmann A, Wollscheid V, Lu H, Ma ZL, Albers P, Schutze K, Rohde V, Behrens P, Dreschers S, Ko Y, Wernert N. 2002. Analysis of microdissected prostate tissue with ProteinChip arrays - a way to new insights into carcinogenesis and to diagnostic tools. Int J Mol Med 9:341-347.
203. White IR, Man WJ, Bryant D, Bugelski P, Camilleri P, Cutler P, Hayes W, Holbrook JD, Kramer K, Lord PG, Wood J. 2003. Protein expression changes in the Sprague-Dawley rat liver proteome following administration of peroxisome proliferator activated receptor alpha and gamma ligands. Proteomics 3:505-512.
204. Wilkins MR, Sanchez JC, Gooley AA, Appel RD, Humphery-Smith I, Hochstrasser DF, Williams KL. 1996. Progress with proteome projects: Why all proteins expressed by a genome should be identified and how to do it. Biotechnol Genet Eng Rev 13:19-50.
205. Wulfkuhle JD, McLean KC, Paweletz CP, Sgroi DC, Trock BJ, Steeg PS, Petricoin EF III. 2001. New approaches to proteomic analysis of breast cancer. Proteomics 1:1205-1215.
206. Wulfkuhle JD, Sgroi DC, Krutzsch H, McLean K, McGarvey K, Knowlton M, Chen S, Shu H, Sahin A, Kurek R, Wallwiener D, Merino MJ, Petricoin EF III, Zhao Y, Steeg PS. 2002. Proteomics of human breast ductal carcinoma in situ. Cancer Res 62:6740-6749.
207. Yates JR. 1996. Protein structure analysis by mass spectrometry. Methods Enzymol 271:351-377.
208. Yates JR III. 1998. Mass spectrometry and the age of the proteome. J Mass Spectrom 33:1-19.
209. Yates JR III, McCormack AL, Schieltz D, Carmack E, Link A. 1997. Direct analysis of protein mixtures by tandem mass spectrometry. J Protein Chem 16:495-497.
210. Yates JR III, Carmack E, Hays L, Link AJ, Eng JK. 1999. Automated protein identification using microcolumn liquid chromatography-tandem mass spectrometry. Methods Mol Biol 112:553-569.
211. Yip TT, Lomas L. 2002. SELDI ProteinChip(R) Array in oncoproteomic research. Technol Cancer Res Treat 1:273-280.
212. Zhou G, Li H, DeCamp D, Chen S, Shu H, Gong Y, Flaig M, Gillespie JW, Hu N, Taylor PR, Emmert-Buck MR, Liotta LA, Petricoin EF III, Zhao Y. 2002. 2D differential in-gel electrophoresis for the identification of esophageal scans cell cancer-specific protein markers. Mol Cell Proteomics 1:117-124.